The Alzheimer’s gene makes brain cells hyperactive years before any symptoms appear
Millions of people carry the APOE4 gene, the strongest known genetic risk factor for Alzheimer’s.
Scientists have known for decades that APOE4 dramatically raises Alzheimer’s risk — one copy triples it, two copies can increase it twelvefold. But the mechanisms behind that risk have remained stubbornly unclear. Now, researchers studying mice have found that hippocampal neurons — the brain cells most critical for forming memories — are both physically smaller and persistently overactive in APOE4 carriers. They fire too readily and too often, a pattern that resembles epileptic activity and, strikingly, mirrors what happens in accelerated cellular aging.
This isn’t just a quirk of overenthusiastic neurons. Chronic hyperexcitability exhausts cells faster, generates more toxic byproducts, and appears to accelerate the buildup of amyloid — the protein whose plaques are a hallmark of Alzheimer’s disease. The researchers also identified a neuronal protein that, when manipulated, could substantially reduce the hyperactivity. That finding points toward a potential intervention target, though whether the same mechanism operates in human brain tissue remains to be confirmed.
A disease that starts decades early
The study fits a growing consensus in Alzheimer’s research: the biological changes that eventually cause dementia begin twenty to thirty years before diagnosis. That gap is both an opportunity and a challenge. Intervening early could theoretically slow or prevent the disease — but treating people for a condition they haven’t yet developed, and may never develop, raises difficult medical and ethical questions.
What makes this particular finding compelling is the link it draws between APOE4, neuronal aging, and disease risk. The cells behave older than they are. If this pattern holds in human subjects — a major if — it could open the door to preventive treatments aimed specifically at APOE4 carriers, a population numbering in the tens of millions globally. That’s a significant market for pharmaceutical development, which may accelerate the pace of follow-up research.
What does this mean for people who carry APOE4?
For now, the practical implications are limited. There is no proven treatment that targets neuronal hyperexcitability in this context, and the findings come from animal models, not human clinical trials. But the research gives scientists a specific, testable mechanism to pursue — a concrete handle on a disease that has resisted treatment for decades. Whether that handle leads anywhere useful, and how quickly, remains an open question.